Genetics, stem cells and consistent dividends can offset the problems of expiring patents
Like this page on Facebook for updates
Friday 20 November 2009
It is easy to get confused over stem cells. It doesn't help that there are several different types of stem cell but the one involved in this proposed clinical trial happens to be the most powerful and the most controversial – embryonic stem cells.
Thursday 19 November 2009
Friday 06 November 2009
Thursday 15 October 2009
The biotechnology minnow Phytopharm received a huge share price boost yesterday after announcing that early trials of its potential Parkinson's disease treatment had produced impressive results.
Tuesday 22 September 2009
Tuesday 15 September 2009
Johnson & Johnson is trying to knock down the price of an 18.4 per cent stake in Irish biotech group Elan Corp after a US judge said the terms of the deal breeched an earlier agreement.
Wednesday 19 August 2009
Monday 08 June 2009
Even the casual observer does not have to try too hard to find evidence of woe in various sectors on the Alternative Investment Market (Aim). For some time (and it has occasionally been chronicled in this column) various companies in high risk sectors like oil and gas exploration and biotechnology have struggled from a lack of funding and all too often business plans that assume too much on the upside.
Thursday 12 March 2009
Wednesday 11 March 2009
Wednesday 25 February 2009
Pharmaceuticals The Swiss giant Roche was rebuffed yesterday in its $42bn (£29bn) hostile bid to buy the shares it does not already own in the US biotech group Genentech.
- 1 French café starts charging extra to rude customers
- 2 Sun will 'flip upside down' within weeks, says Nasa
- 3 Australia incest case: Deformed children found in remote farming community after generations of inbreeding
- 4 Physicists discover 'clearest evidence yet' that the Universe is a hologram
- 5 Fox News presenter tells viewers it is a 'fact' that both Jesus and Santa Claus are white